Eli Lilly posts mixed quarter even as demand for weight loss, diabetes drugs soars

The Lilly Biotechnology Center in San Diego, California, on March 1, 2023.

Mike Blake | Reuters

Eli Lilly on Thursday reported mixed results for the fourth quarter as sales of its blockbuster weight loss and diabetes drugs soared but it saw lower realized prices.

The figures were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors. Eli Lilly had slashed its 2024 revenue guidance, as it said demand for its weight loss and diabetes drugs would not meet its lofty expectations.

The company’s earnings topped Wall Street estimates, but sales fell just short.

Here’s what Eli Lilly reported for the period compared with what Wall Street was expecting, based on a survey of analysts by LSEG:

Earnings per share: $5.32 adjusted vs. $4.95 expected
Revenue: $13.53 billion vs. $13.57 billion expected

This story is developing. Please check back for updates.

Source

Health

MAHA loves dietary supplements. But that hasn’t led to gains in Washington — yet.

August 26, 2025

An avid consumer of dietary supplements, Health and Human Services Secretary Robert F. Kennedy Jr. has surrounded himself in part with senior staff members, advisers and health influencers who have promoted everything from weight loss pills to capsules of desiccated organ meat. But that hasn’t led to gains in Washington for the multibillion-dollar industry — yet. […]

Health

Eli Lilly’s weight loss pill orforglipron clears its latest trial, paving way for approval

August 26, 2025

Eli Lilly Biotechnology Center is shown in San Diego, California, U.S. March 1, 2023. Mike Blake | Reuters Eli Lilly on Tuesday said its daily weight loss pill helped patients with obesity and Type 2 diabetes shed weight in a late-stage trial, meeting the study’s main goal and clearing the way for the company to […]

Health

A world on weight loss drugs: How GLP-1s are reshaping the economy

August 26, 2025

Eternalcreative | Istock | Getty Images Miracle drugs, obesity treatments and skinny jabs. Call them what you will, few drugs have had a more transformative effect on Wall Street and waistlines over recent decades than GLP-1s. Familiarly known under the brand names Wegovy and Zepbound, Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of medication used to […]